期刊文献+
共找到219篇文章
< 1 2 11 >
每页显示 20 50 100
What are the effects of proton pump inhibitors on the small intestine? 被引量:8
1
作者 Shunji Fujimori 《World Journal of Gastroenterology》 SCIE CAS 2015年第22期6817-6819,共3页
Generally, proton-pump inhibitors(PPIs) have great benefit for patients with acid related disease with less frequently occurring side effects. According to a recent report, PPIs provoke dysbiosis of the small intestin... Generally, proton-pump inhibitors(PPIs) have great benefit for patients with acid related disease with less frequently occurring side effects. According to a recent report, PPIs provoke dysbiosis of the small intestinal bacterial flora, exacerbating nonsteroidal anti-inflammatory drug-induced small intestinal injury.Several meta-analyses and systematic reviews have reported that patients treated with PPIs, as well as post-gastrectomy patients, have a higher frequency of small intestinal bacterial overgrowth(SIBO) compared to patients who lack the aforementioned conditions.Furthermore, there is insufficient evidence that these conditions induce Clostridium difficile infection. At this time, PPI-induced dysbiosis is considered a type of SIBO. It now seems likely that intestinal bacterial flora influence many diseases, such as inflammatory bowel disease, diabetes mellitus, obesity, nonalcoholic fatty liver disease, and autoimmune diseases.When attempting to control intestinal bacterial flora with probiotics, prebiotics, and fecal microbiota transplantation, etc., the influence of acid suppression therapy, especially PPIs, should not be overlooked. 展开更多
关键词 Proton-pump inhibitors NONSTEROIDAL antiinflammatorydrug small intestine DYSBIOSIS smallintestinal BACTERIAL OVERGROWTH
下载PDF
AN ANALYTICAL SOLUTION FOR THE MODEL OF DRUG DISTRIBUTION AND ABSORPTION IN SMALL INTESTINE 被引量:4
2
作者 Xu Mingyu (Department of Mathematics,Shandong University,Jinan,250100,China) 《Acta Mechanica Sinica》 SCIE EI CAS CSCD 1990年第4期316-323,共8页
According to the physiological and anatomical characteristics of small intestine,neglecting the effect of its motility on the distribution and absorption of drug and nutrient,Y.Miyamoto et al.proposed a model of two-d... According to the physiological and anatomical characteristics of small intestine,neglecting the effect of its motility on the distribution and absorption of drug and nutrient,Y.Miyamoto et al.proposed a model of two-dimensional laminar flow in a circular porous tube with permeable wall and calculated the concentration profile of drugby numerical analysis.In this paper,we give a steady-state analytical solution of the above model including deactivationterm.The obtained results are in agreement with the results of their numerical analysis. Moreover the analytical solution presented in this paper reveals the relation among the physiological parameters of the model and describes the basic absorption rule of drug and nutrient through the intestinal wall and hence pro- vides a theoretical basis for determining the permeability and reflection coefficient through in situ experiments. 展开更多
关键词 drug and nutrient distribution and absorption in small intestine model and analytical solution
下载PDF
Inhibitory effect and mechanism of acarbose combined with gymnemic acid on maltose absorption in rat intestine 被引量:2
3
作者 Toshiaki Imoto Yasutake Hiji 《World Journal of Gastroenterology》 SCIE CAS CSCD 2001年第1期9-15,共7页
AIM To compare the combinative andindividual effect of acarbose and gymnemic acid(GA) on maltose absorption and hydrolysis insmall intestine to determine whether nutrientcontrol in diabetic care can be improved bycomb... AIM To compare the combinative andindividual effect of acarbose and gymnemic acid(GA) on maltose absorption and hydrolysis insmall intestine to determine whether nutrientcontrol in diabetic care can be improved bycombination of them.METHODS The absorption and hydrolysis ofmaltose were studied by cyclic perfusion ofintestinal loops in situ and motility of theintestine was recorded with the intestinal ring invitro using Wistar rats.RESULTS The total inhibitory rate of maltoseabsorption was improved by the combination ofGA (0.1 g/L 1.0 g/L) and acarbose(0.1 mmol/L 2.0 mmol/L) throughout theireffective duration (P<0.05, U test of Mann-Whitney), although the improvement only couldbe seen at a Iow dosage during the first hour.With the combination, inhibitory duration of acarbose on maltose absorption was prolonged to 3 h and the inhibitory effect onset of GA was fastened to 15min. GA suppressed the intestinal mobility with a good correlation (r-0.98) to the inhibitory effect of GA on maltose absorption and the inhibitory effect of 2mmol/L (high dose) acarbose on maltose hydrolysis was dual modulated by 1 g/L GA in vivo indicating that the combined effects involved the functional alteration of intestinal barriers.CONCLUSION There are augmented effects of acarbose and GA, which involve pre-cellular and paracellular barriers. Diabetic care can be improved by employing the combination. 展开更多
关键词 diabetes MELLITUS MALTOSE gymnemic ACID alpha-glucosidases intestinAL MUCOSA rats nutrition
下载PDF
3D organoids derived from the small intestine:An emerging tool for drug transport research 被引量:5
4
作者 Yuanjin Zhang Shengbo Huang +3 位作者 Weiguo Zhong Wenxia Chen Bingyi Yao Xin Wang 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2021年第7期1697-1707,共11页
Small intestine in vitro models play a crucial role in drug transport research.Although conventional 2 D cell culture models,such as Caco-2 monolayer,possess many advantages,they should be interpreted with caution bec... Small intestine in vitro models play a crucial role in drug transport research.Although conventional 2 D cell culture models,such as Caco-2 monolayer,possess many advantages,they should be interpreted with caution because they have relatively poor physiologically reproducible phenotypes and functions.With the development of 3 D culture technology,pluripotent stem cells(PSCs)and adult somatic stem cells(ASCs)show remarkable self-organization characteristics,which leads to the development of intestinal organoids.Based on previous studies,this paper reviews the application of intestinal 3 D organoids in drug transport mediated by P-glycoprotein(P-gp),breast cancer resistance protein(BCRP)and multidrug resistance protein 2(MRP2).The advantages and limitations of this model are also discussed.Although there are still many challenges,intestinal 3 D organoid model has the potential to be an excellent tool for drug transport research. 展开更多
关键词 3D organoid small intestine drug transporter Caco-2 cell monolayer P-GLYCOPROTEIN
原文传递
Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury 被引量:16
5
作者 Sung Chul Park Hoon Jai Chun +1 位作者 Chang Don Kang Donggeun Sul 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第42期4647-4653,共7页
Non-steroidal anti-inflammatory drug Nindu cedsmall bowel injury is a topi that deserves attentionsin e the advent of apsule endos opy and balloon enteros opy. N enteropathy is ommon and is mostly asymptomati . Howeve... Non-steroidal anti-inflammatory drug Nindu cedsmall bowel injury is a topi that deserves attentionsin e the advent of apsule endos opy and balloon enteros opy. N enteropathy is ommon and is mostly asymptomati . However,massive bleeding,stri ture,or perforation may o ur. The pathogenesis of small intestine injury by N s is omplex and different from that of the upper gastrointestinal tra t. No drughas yet been developed that an ompletely preventor treat N enteropathy. There fore,a long-termr and omized study in hroni N users is needed. 展开更多
关键词 非甾体抗炎药 消炎药 小肠 损伤 预防 管理 发病机制 双气囊
下载PDF
Non-steroidal anti-inflammatory drugs-induced small intestinal injury and probiotic agents 被引量:3
6
作者 Mario Guslandi 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第31期4241-4242,共2页
Intestinal bacteria play a role in the development of non-steroidal anti-inflammatory drugs(NSAID)-induced small intestinal injury.Agents such as probiotics,able to modify the gut ecology,might theoretically be useful... Intestinal bacteria play a role in the development of non-steroidal anti-inflammatory drugs(NSAID)-induced small intestinal injury.Agents such as probiotics,able to modify the gut ecology,might theoretically be useful in preventing small intestinal damage induced by NSAIDs.The clinical studies available so far do suggest that some probiotic agents can be effective in this respect. 展开更多
关键词 非甾体类抗炎药 微生态制剂 损伤 小肠 肠道细菌 消炎药 类固醇 益生菌
下载PDF
Effect of prolonged omeprazole administration on segmental intestinal Mg2+ absorption in male Sprague-Dawley rats 被引量:3
7
作者 Nasisorn Suksridechacin Punnisa Kulwong +1 位作者 Siriporn Chamniansawat Narongrit Thongon 《World Journal of Gastroenterology》 SCIE CAS 2020年第11期1142-1155,共14页
BACKGROUND The exact mechanism of proton pump inhibitors(PPIs)-induced hypomagnesemia(PPIH) is largely unknown. Previous studies proposed that PPIH is a consequence of intestinal Mg2+ malabsorption. However, the mecha... BACKGROUND The exact mechanism of proton pump inhibitors(PPIs)-induced hypomagnesemia(PPIH) is largely unknown. Previous studies proposed that PPIH is a consequence of intestinal Mg2+ malabsorption. However, the mechanism of PPIs-suppressed intestinal Mg2+ absorption is under debate.AIM To investigate the effect of 12-wk and 24-wk omeprazole injection on the total,transcellular, and paracellular Mg2+ absorption in the duodenum, jejunum, ileum,and colon of male Sprague-Dawley rats.METHODS The rats received 20 mg/kg·d subcutaneous omeprazole injection for 12 or 24 wk.Plasma and urinary Mg2+, Ca2+, and PO43-levels were measured. The plasma concentrations of 1α,25-dihydroxyvitamin D3(1α,25(OH)2D3), parathyroid hormone(PTH), fibroblast growth factor 23(FGF-23), epidermal growth factor(EGF), and insulin were also observed. The duodenum, jejunum, ileum, and colon of each rat were mounted onto individual modified Using chamber setups to study the rates of total, transcellular, and paracellular Mg2+ absorption simultaneously. The expression of transient receptor potential melastatin 6(TRPM6) and cyclin M4(CNNM4) in the entire intestinal tract was also measured.RESULTS Single-dose omeprazole injection significantly increased the intraluminal p H of the stomach, duodenum, and jejunum. Omeprazole injection for 12 and 24 wk induced hypomagnesemia with reduced urinary Mg2+ excretion. The plasma Ca2+ was normal but the urinary Ca2+ excretion was reduced in rats with PPIH. The plasma and urinary PO43-levels increased in PPIH rats. The levels of1α,25(OH)2D3 and FGF-23 increased, whereas that of plasma EGF decreased in the omeprazole-treated rats. The rates of the total, transcellular, and paracellular Mg2+ absorption was significantly lower in the duodenum, jejunum, ileum, and colon of the rats with PPIH than in those of the control rats. The percent suppression of Mg2+ absorption in the duodenum, jejunum, ileum, and colon of the rats with PPIH compared with the control rats was 81.86%, 70.59%, 69.45%,and 39.25%, respectively. Compared with the control rats, the rats with PPIH had significantly higher TRPM6 and CNNM4 expression levels throughout the intestinal tract.CONCLUSION Intestinal Mg2+ malabsorption was observed throughout the intestinal tract of rats with PPIH. PPIs mainly suppressed small intestinal Mg2+ absorption. Omeprazole exerted no effect on the intraluminal acidic pH in the colon. Thus, the lowest percent suppression of total Mg2+ absorption was found in the colon. The expression levels of TRPM6 and CNNM4 increased, indicating the presence of a compensatory response to Mg2+ malabsorption in rats with PPIH. Therefore, the small intestine is an appropriate segment that should be modulated to counteract PPIH. 展开更多
关键词 ADVERSE effect Colon Mg2+absorption Proton pump inhibitors-induced HYPOMAGNESEMIA small intestine
下载PDF
Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury 被引量:2
8
作者 Chen Huang Bin Lu +4 位作者 Yi-Hong Fan Lu Zhang Ning Jiang Shuo Zhang Li-Na Meng 《World Journal of Gastroenterology》 SCIE CAS 2014年第31期11012-11018,共7页
AIM: To evaluate the effect of muscovite in preventing small bowel injury induced by nonsteroidal anti-inflammatory drugs(NSAIDs).METHODS: We recruited and screened thirty-two healthy volunteers who were randomly allo... AIM: To evaluate the effect of muscovite in preventing small bowel injury induced by nonsteroidal anti-inflammatory drugs(NSAIDs).METHODS: We recruited and screened thirty-two healthy volunteers who were randomly allocated equally into two groups: an NSAID control group, who received 75 mg slow-release diclofenac, twice daily for 14 d; and an NSAID-muscovite group, who received 3 g of muscovite in addition to the 75 mg of slow-release diclofenac, twice daily for 14 d. For gastroprotection, both groups were administered 20 mg/d of the proton pump inhibitor omeprazole. All eligible subjects underwent video capsule endoscopy(CE) prior to and 14 d after treatment.RESULTS: Thirty subjects(NSAID-muscovite group,n =16; NSAID control group, n =14) finally completed the whole trail. At the baseline CE examination, no statistically significant differences between the two groups have been observed. However, after 14 d of drug treatment, a significant difference was observed in the percentage of subjects with mucosal breaks when comparing the NSAID-muscovite group with the NSAID control group. While 71.4%(10/14) of subjects in the NSAID control group had at least one mucosal break, co-administration of muscovite in the NSAID-muscovite group reduced the rate to 31.3%(5/16)(P = 0.028). Moreover, higher number of mucosal breaks was found in the NSAID control group vs that in the NSAID-muscovite group(P < 0.05).CONCLUSION: Muscovite co-therapy reduced the incidence of small intestinal injury after 14 d of diclofenac administration. 展开更多
关键词 MUSCOVITE NONSTEROIDAL ANTI-INFLAMMATORY drugS Sma
下载PDF
Mycophenolate mofetil toxicity mimicking acute cellular rejection in a small intestinal transplant
9
作者 Ross Apostolov Khashayar Asadi +2 位作者 Julie Lokan Ning Kam Adam Testro 《World Journal of Transplantation》 2017年第1期98-102,共5页
Mycophenolate mofetil(MMF) is an important medication used for maintenance immunosuppression in solid organ transplants. A common gastrointestinal(GI) side effect of MMF is enterocolitis, which has been associated wit... Mycophenolate mofetil(MMF) is an important medication used for maintenance immunosuppression in solid organ transplants. A common gastrointestinal(GI) side effect of MMF is enterocolitis, which has been associated with multiple histological features. There is little data in the literature describing the histological effects of MMF in small intestinal transplant(SIT) recipients. We present a case of MMF toxicity in a SIT recipient, with histological changes in the donor ileum mimicking persistent acute cellular rejection(ACR). Concurrent biopsies of the patient's native colon showed similar changes to those from the donor small bowel, suggesting a non-graft specific process, raising suspicion for MMF toxicity. The MMF was discontinued and complete resolution of these changes occurred over three weeks. MMF toxicity should therefore be considered as a differential diagnosis for ACR and graftversus-host disease in SITs. 展开更多
关键词 small intestinAL transplantation drug TOXICITY MYCOPHENOLATE mofetil Acute cellular REJECTION IMMUNOSUPPRESSION
下载PDF
胃食管反流病并小肠细菌过度生长患者的临床特征及利福昔明治疗效果研究
10
作者 吴洁 董魁 +3 位作者 王军 乔冠恩 李森 武向丽 《现代消化及介入诊疗》 2024年第1期36-39,47,共5页
目的 探究胃食管反流病(GERD)并小肠细菌过度生长(SIBO)患者的临床特征,并进一步探究利福昔明对此类患者治疗效果。方法 统计2022年1月至2023年01月就诊于邯郸市中心医院及邯郸市第一医院的符合胃食管反流病纳入标准的患者149例,依据乳... 目的 探究胃食管反流病(GERD)并小肠细菌过度生长(SIBO)患者的临床特征,并进一步探究利福昔明对此类患者治疗效果。方法 统计2022年1月至2023年01月就诊于邯郸市中心医院及邯郸市第一医院的符合胃食管反流病纳入标准的患者149例,依据乳果糖氢-甲烷呼气试验(LHBT)结果,将其分为GERD合并SIBO组(GERD-P组)与不合并SIBO组(GERD-N组)。比较两组在一般资料(性别、年龄、体重指数BMI)与临床资料(不典型症状、食管外症状、并发症、内镜下表现、GERDQ评分、RDQ评分、GERD-HRQL评分)方面的区别。随后将GERD-P组随机分为治疗组(给予艾普拉唑10 mg qd联合利福昔明0.2 g tid治疗4周)和对照组(单独给予艾普拉唑10 mg qd治疗4周),通过临床资料评价利福昔明治疗效果。结果GERD-P组与GERD-N组相比,两组性别比例、年龄无差异(P>0.05),GERD-P组的BMI,不典型症状、食管外症状及并发症比例,内镜下表现严重程度,GERDQ评分,RDQ评分,GERD-HRQL评分均高于GERD-N组,有统计学意义(P<0.05)。治疗4周后,治疗组与对照组相比,两组在并发症方面无差异(P>0.05),治疗组在不典型症状、食管外症状、内镜下表现缓解情况及GERDQ评分、RDQ评分、GERD-HRQL评分方面均优于对照组,有统计学意义(P<0.05)。结论 高BMI的GERD患者更容易合并SIBO,GERD合并SIBO患者的临床症状及相关量表评分均较GERD不合并SIBO患者严重。对合并SIBO的GERD患者,艾普拉唑联合利福昔明治疗临床效果优于单独艾普拉唑治疗效果。 展开更多
关键词 胃食管反流病 小肠细菌过度生长 利福昔明 疗效
下载PDF
紫杉醇药物涂层球囊治疗老年冠状动脉小血管病变的效果分析
11
作者 杨亚兵 孙绪志 黄江燕 《大医生》 2024年第4期34-37,共4页
目的 分析紫杉醇药物涂层球囊对老年冠状动脉小血管病变患者的治疗效果,为临床提供参考。方法 回顾性分析2021年1月至2022年1月北京市仁和医院收治的88例行经皮冠状动脉介入治疗(PCI)术的老年冠状动脉小血管病变患者的临床资料。根据术... 目的 分析紫杉醇药物涂层球囊对老年冠状动脉小血管病变患者的治疗效果,为临床提供参考。方法 回顾性分析2021年1月至2022年1月北京市仁和医院收治的88例行经皮冠状动脉介入治疗(PCI)术的老年冠状动脉小血管病变患者的临床资料。根据术中介入治疗方案不同分为药物涂层球囊(DCB)组(49例,给予紫杉醇药物涂层球囊治疗)与药物洗脱支架(DES)组(39例,给予雷帕霉素支架治疗)。比较两组患者治疗效果、造影结果、主要心脏不良事件(MACE)发生情况及出血情况。结果 DCB组患者整体疗效优于DES组,且总有效率高于DES组(P<0.05)。术后即刻,两组患者最小血管直径大于术前、血管狭窄程度小于术前,且DCB组最小血管直径大于DES组、血管狭窄程度小于DES组(P<0.05);术后8个月,DCB组的晚期管腔丢失(LLL)水平低于DES组(P<0.05)。术后12个月,两组患者MACE总发生率比较,差异无统计学意义(P>0.05)。术后12个月,DCB组患者出血总发生率低于DES组(P<0.05)。结论 PCI中予紫杉醇药物涂层球囊治疗老年冠状动脉小血管病变患者,可有效预防患者二次狭窄,保障治疗效果与安全性。 展开更多
关键词 紫杉醇药物涂层球囊 老年冠状动脉小血管病变 治疗效果
下载PDF
药物小分子穿越磷脂双层膜输运过程中的时滞效应 被引量:1
12
作者 王凡 张菁菁 +1 位作者 蒋中英 赵新军 《原子与分子物理学报》 CAS 北大核心 2024年第1期1-8,共8页
本文基于扩散动力学,建立了一种新的药物小分子穿越磷脂双层膜输运的理论模型,研究药物小分子穿越磷脂双层膜输运的动态过程,考察药物小分子跨膜输运过程中的时间延迟(时滞)效应.研究发现,药物小分子在数分钟内穿越磷脂双层膜各区域进... 本文基于扩散动力学,建立了一种新的药物小分子穿越磷脂双层膜输运的理论模型,研究药物小分子穿越磷脂双层膜输运的动态过程,考察药物小分子跨膜输运过程中的时间延迟(时滞)效应.研究发现,药物小分子在数分钟内穿越磷脂双层膜各区域进入细胞,由于时滞效应,穿膜过程呈现了周期性演化特性.当药物小分子数量增加到一定程度,磷脂分子层会出现微小孔,让积累的药物小分子快速通过.通过分析模型中各参数的敏感性,我们还发现,药物小分子在磷脂双层膜内不同区域的扩散特性,以及输运过程的时滞性,都会对药物小分子穿越磷脂双层膜的动力学有较大程度的影响.理论结果符合模拟、实验观测,进一步深刻揭示了药物小分子穿越磷脂双层膜的穿膜特性,可为设计确切的疗法药物提供必要的参考和新方案. 展开更多
关键词 药物小分子 磷脂双层膜 时滞效应
下载PDF
奥希替尼在老年非小细胞肺癌患者靶向治疗中的应用效果及对T细胞水平的影响
13
作者 吴俊沛 方权 +1 位作者 朱晓丹 吴洪 《中国药物与临床》 CAS 2024年第8期491-496,共6页
目的 探讨奥西替尼在老年非小细胞肺癌患者靶向治疗中的效果及对免疫水平的影响。方法 回顾性选择2018年1月至2020年12月老年非小细胞肺癌患者116例研究,根据治疗方法不同分为2组,各58例。对照组采用常规放化疗治疗,观察组在对照组基础... 目的 探讨奥西替尼在老年非小细胞肺癌患者靶向治疗中的效果及对免疫水平的影响。方法 回顾性选择2018年1月至2020年12月老年非小细胞肺癌患者116例研究,根据治疗方法不同分为2组,各58例。对照组采用常规放化疗治疗,观察组在对照组基础上联合奥西替尼治疗,3个月治疗后评估患者效果,比较2组总有效率、T细胞水平(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、肿瘤标志物水平、不良反应发生率。结果 观察组治疗3个月总有效率为44.8%高于对照组25.9%(P<0.05);2组治疗后3个月CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均低于治疗前(P<0.05);CD8^(+)水平高于治疗前(P<0.05);观察组治疗后3个月CD3^(+)(58.95±4.21)%、CD4^(+)(32.59±3.11)%、CD4^(+)/CD8^(+)(1.21±0.22)高于对照组(P<0.05);CD8^(+)(26.81±3.32)%低于对照组(P<0.05);观察组干预3个月后CA125(91±8)U/ml、CYFRA21-1(1.26±0.24)μg/L及癌胚抗原(CEA)水平(34±5)μg/L均低于对照组(P<0.05);2组不良反应发生率差异无统计学意义(P>0.05)。结论 奥西替尼用于老年非小细胞肺癌患者靶向治疗中,能获得较好的总有效率,对患者T细胞水平影响较小,可降低肿瘤标志物水平,未增加不良反应发生率,值得临床推广应用。 展开更多
关键词 非小细胞肺 分子靶向治疗 T淋巴细胞 生物标记 肿瘤 药物相关性副作用和不良反应 奥西替尼
下载PDF
生物制剂和小分子药物治疗溃疡性结肠炎有效性与安全性的网状Meta分析
14
作者 谭书法 张磊昌 +2 位作者 高强强 欧艳 黄水兰 《中国全科医学》 CAS 北大核心 2024年第17期2155-2166,共12页
背景溃疡性结肠炎(UC)是一种慢性复发和缓解性免疫介导的炎症性肠病,其治疗方式还存在争议,大约一半的患者病程发展复杂,伴有慢性活动或频繁复发的UC症状,严重影响了患者的生活质量。目的目前UC的治疗方式越来越多,本研究旨在比较生物... 背景溃疡性结肠炎(UC)是一种慢性复发和缓解性免疫介导的炎症性肠病,其治疗方式还存在争议,大约一半的患者病程发展复杂,伴有慢性活动或频繁复发的UC症状,严重影响了患者的生活质量。目的目前UC的治疗方式越来越多,本研究旨在比较生物制剂和小分子药物治疗UC患者的相对疗效和安全性。方法2名研究人员独立使用PubMed、Embase、Web of Science、Cochrane Library、中国知网、万方数据知识服务平台、维普网数据库搜索有关生物制剂和小分子药物治疗UC的随机对照试验,干预组为生物制剂或小分子药物,对照组为安慰剂。采用Cochrane偏倚风险工具、RevMan 5.4对纳入研究进行质量评价,采用R Studio进行成对分析和网络荟萃分析,采用累积排序概率图下面积(SUCRA)对各结局指标的纳入药物进行排序,以比较不同治疗方式对UC的临床疗效。结果共纳入25项研究,包括9546例UC患者,10种药物干预方案(Filgotinib 100 mg、Filgotinib 200 mg、Upadacitinib、Tofacitinib、Etrolizumab、Adalimumab、Vedolizumab、Golimumab 50 mg、Golimumab 100 mg、Infliximab)。各药物对临床缓解效果的SUCRA概率排序结果显示,Upadacitinib(94.1%)>Vedolizumab(85.1%)>Tofacitinib(74.3%)>Infliximab(72.7%)>Filgotinib 200 mg(51.5%)>Golimumab 100 mg(44.3%)>Golimumab 50 mg(39.3%)>Etrolizumab(38.9%)>Adalimumab(29.8%)>Filgotinib 100 mg(18.7%)>Placebo(0.7%)。各药物对临床反应效果的SUCRA概率排序结果显示,Upadacitinib(98.4%)>Infliximab(84.4%)>Tofacitinib(67.2%)>Vedolizumab(58.4%)>Golimumab50 mg(53.3%)>Adalimumab(34.6%)>Golimumab 100 mg(30.1%)>Placebo(0.4%)。各药物对内镜缓解效果的SUCRA概率排序结果显示,Upadacitinib(98.7%)>Tofacitinib(68.6%)>Filgotinib 200 mg(59.6%)>Adalimumab(55.2%)>Etrolizumab(46.0%)>Vedolizumab(45.9%)>Filgotinib 100 mg(23.4%)>Placebo(2.2%)。各药物对黏膜愈合效果的SUCRA概率排序结果显示,Upadacitinib(99.7%)>Tofacitinib(77.2%)>Infliximab(65.2%)>Golimumab 50 mg(46.4%)>Vedolizumab(44.4%)>Adalimumab(33.8%)>Golimumab 100 mg(31.9%)>Placebo(1.0%)。各药物不良事件风险的SUCRA概率排序结果显示,Golimumab 100 mg(96.7%)>Golimumab 50 mg(92.1%)>Placebo(68.7%)>Tofacitinib(60.8%)>Adalimumab(60.7%)>Etrolizumab(47.2%)>Upadacitinib(42.2%)>Vedolizumab(41.3%)>Infliximab(27.0%)>Filgotinib 200 mg(6.6%)>Filgotinib 100 mg(6.2%)。结论Upadacitinib在临床反应、临床缓解、黏膜愈合以及内镜缓解方面均展现出最佳效用,在不良事件方面Filgotinib 100 mg表现出更为安全的结果。 展开更多
关键词 溃疡性结肠炎 生物制剂 小分子药物 临床疗效 网状Meta分析
下载PDF
信迪利单抗致免疫性肠炎引发肠道大出血1例
15
作者 孟保伟 吴才志 +6 位作者 马永明 常瑞同 杨小刚 田华山 武志强 尹蕊 朱自江 《药物流行病学杂志》 CAS 2024年第7期818-823,共6页
1例68岁非小细胞肺鳞癌患者接受6周期信迪利单抗联合化疗后,予信迪利单抗200 mg,ivd单药治疗出现严重腹泻、腹痛、便血等不适,彩超及肠镜表明肠道广泛充血炎症,病理活检综合考虑为急性免疫性肠炎。暂停免疫治疗,给予足量糖皮质激素及对... 1例68岁非小细胞肺鳞癌患者接受6周期信迪利单抗联合化疗后,予信迪利单抗200 mg,ivd单药治疗出现严重腹泻、腹痛、便血等不适,彩超及肠镜表明肠道广泛充血炎症,病理活检综合考虑为急性免疫性肠炎。暂停免疫治疗,给予足量糖皮质激素及对症治疗,2 d后患者腹泻、便血好转,6 d后症状缓解恢复正常。经评估,该患者免疫性肠炎不良反应与信迪利单抗的关联性为很可能有关。本文通过对信迪利单抗致免疫相关性肠炎的病例进行文献复习,阐述如何在临床中运用实验室检查、肠镜等检测其病理改变并结合临床腹泻、便血等表现进行诊断鉴别,参考指南分级进行及时处理,并根据本病例加以讨论,以期提高临床医师相关场景下的识别和处理能力。 展开更多
关键词 信迪利单抗 非小细胞肺癌 免疫性肠炎 肠道出血 药品不良反应
下载PDF
养肺益气汤联合载药微球支气管动脉化疗在非小细胞肺癌治疗中的临床效果分析
16
作者 陆凯娟 徐佳丽 +1 位作者 张娟 陈红英 《中外医学研究》 2024年第6期18-21,共4页
目的:分析养肺益气汤联合载药微球支气管动脉化疗治疗非小细胞肺癌的临床效果。方法:选择2020年1月—2023年1月启东市中医院肿瘤科收治的82例非小细胞肺癌患者,根据随机数表法分为化疗组、联用组,各41例。其中化疗组采用载药微球支气管... 目的:分析养肺益气汤联合载药微球支气管动脉化疗治疗非小细胞肺癌的临床效果。方法:选择2020年1月—2023年1月启东市中医院肿瘤科收治的82例非小细胞肺癌患者,根据随机数表法分为化疗组、联用组,各41例。其中化疗组采用载药微球支气管动脉化疗治疗,而联用组采用养肺益气汤联合载药微球支气管动脉化疗治疗。比较两组肿瘤标志物、中医症候积分、毒副作用发生率。结果:治疗前,两组肿瘤标志物比较,差异无统计学意义(P>0.05);治疗后,两组肿瘤标志物均低于治疗前,且联用组低于化疗组,差异有统计学意义(P<0.05)。治疗前,两组中医症候积分比较,差异无统计学意义(P>0.05);治疗后,两组中医症候积分均低于治疗前,且联用组低于化疗组,差异有统计学意义(P<0.05)。联用组毒副作用总发生率低于化疗组,差异有统计学意义(P<0.05)。结论:在针对非小细胞肺癌进行治疗时,在载药微球支气管动脉化疗基础上予以养肺益气汤治疗能够进一步控制癌症病变,缓解各项临床症状,并降低毒副作用发生的可能性。 展开更多
关键词 养肺益气汤 载药微球支气管动脉化疗 非小细胞肺癌 肿瘤标志物 毒副作用
下载PDF
替雷利珠联合化疗治疗非小细胞肺癌手术患者的效果
17
作者 高薇薇 邵春艳 +2 位作者 姜洁 王欢 张磊 《中国药物应用与监测》 CAS 2024年第2期106-109,共4页
目的评价替雷利珠单抗在含铂双药化疗治疗的非小细胞肺癌手术患者中的应用效果。方法选取2022年1月—2023年12月收治的100例拟行手术治疗的非小细胞肺癌患者,根据随机数字表法将其分成两组。对照组50例患者在术前给予含铂双药治疗,观察... 目的评价替雷利珠单抗在含铂双药化疗治疗的非小细胞肺癌手术患者中的应用效果。方法选取2022年1月—2023年12月收治的100例拟行手术治疗的非小细胞肺癌患者,根据随机数字表法将其分成两组。对照组50例患者在术前给予含铂双药治疗,观察组50例患者在其治疗基础上加用替雷利珠单抗治疗。比较两组临床疗效、无事件及无疾病生存率、生活质量改善情况、不良反应。结果观察组临床疗效(完全缓解率:20.00%vs.10.00%)及病理评估(主要病理学缓解率:46.00%vs.20.00%)优于对照组(Z=3.484,P<0.001;χ^(2)=7.664,P=0.006);Kaplan-Meier生存分析显示,观察组无事件生存率(84.00%vs.60.00%)及无疾病生存率(78.00%vs.60.00%)均高于对照组(χ^(2)=4.298,P=0.038;χ^(2)=4.783,P=0.029);在生活质量改善率方面,观察组(64.00%)较对照组高(42.00%),差异有统计学意义(χ^(2)=4.857,P=0.028);两组不良反应发生率(18.00%vs.22.00%)比较,差异无统计学意义(χ^(2)=0.250,P=0.617)。结论在含铂双药化疗治疗非小细胞肺癌手术患者中的实施替雷利珠单抗治疗可提高治疗效果,促进生活质量改善,且不会增加不良反应发生风险。 展开更多
关键词 非小细胞肺癌 替雷利珠单抗 含铂双药 临床疗效 不良反应
下载PDF
PD-1抑制剂联合抗血管生成药物治疗晚期NSCLC的疗效及安全性分析
18
作者 魏小寒 王国祥 《四川医学》 CAS 2024年第6期607-612,共6页
目的探讨程序性死亡蛋白-1(PD-1)抑制剂联合抗血管生成药物治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法选取我院2019年1月至2021年11月收治的137例晚期NSCLC患者作为研究对象,按治疗方法分为两组。PD-1抑制剂联合抗血管生成药物... 目的探讨程序性死亡蛋白-1(PD-1)抑制剂联合抗血管生成药物治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法选取我院2019年1月至2021年11月收治的137例晚期NSCLC患者作为研究对象,按治疗方法分为两组。PD-1抑制剂联合抗血管生成药物治疗者81例(联合组),PD-1抑制剂单药治疗者56例(单药组)。统计分析两组客观缓解率(ORR)、疾病控制率(DCR)、无进展生存时间(PFS)、总生存时间(OS)、血管内皮生长因子(VEGF)、肿瘤体积(TV)、预后生存曲线及毒副反应相关数据。结果联合组ORR和DCR显著高于单药组,差异有统计学意义(χ^(2)=4.219,3.583;P=0.040,0.045);联合组PFS和OS均显著长于单药组,差异有统计学意义(Z=7.017,5.778;P<0.001);两组治疗后VEGF和TV水平均明显下降(P<0.001),且治疗1、2个周期后联合组VEGF和TV水平均显著低于单药组,差异有统计学意义(P<0.001);两组Kaplan-Meier预后生存曲线比较差异有统计学意义(χ^(2)_(L)=5.338,P=0.027);两组患者恶心呕吐、头疼、疲劳、腹泻、皮疹、贫血、便秘、呼吸困难及关节痛发生率和Ⅲ级以上毒副反应发生率比较,差异无统计学意义(P>0.05)。结论PD-1抑制剂联合抗血管生成药物可抑制肿瘤微血管增生,缩小TV,提高ORR和DCR,延长PFS和OS,Ⅲ级以上毒副反应发生率低,毒副反应总体安全可控,有助于增加晚期NSCLC患者获益。 展开更多
关键词 非小细胞肺癌 晚期 程序性死亡蛋白-1 抗血管生成药物 安全性 疗效
下载PDF
磁控机器人胶囊内镜在药物相关性小肠黏膜损伤诊断中的应用价值
19
作者 秦黄雯 陈朝宇 +2 位作者 杨燕玲 朱金水 张靖 《胃肠病学和肝病学杂志》 CAS 2024年第3期247-249,共3页
目的探索磁控机器人胶囊内镜(magnetic control robot capsule endoscopy,MCRCE)在药物相关性小肠黏膜损伤中的诊断价值。方法收集2021年9月至2021年12月共119例于我院接受MCRCE检查的患者,询问患者病史及服用治疗心血管疾患药物史,根... 目的探索磁控机器人胶囊内镜(magnetic control robot capsule endoscopy,MCRCE)在药物相关性小肠黏膜损伤中的诊断价值。方法收集2021年9月至2021年12月共119例于我院接受MCRCE检查的患者,询问患者病史及服用治疗心血管疾患药物史,根据患者服用药物状况分为未服药组和服药组,以调查问卷形式,分别统计两组患者的相关信息,采用GraphPad Prism 8.0.1软件进行t检验和χ2检验。结果两组患者年龄、肠道黏膜病变检出率及病变数量比较,差异均有显著统计学意义(P<0.0001),但性别、BMI、幽门螺杆菌感染及饮食习惯方面差异均无统计学意义(P>0.05)。结论服用抗凝药及降压药会造成肠道黏膜的损伤且更易发生多处损伤,MCRCE对肠黏膜损伤具有良好的诊断价值。 展开更多
关键词 磁控机器人胶囊内镜 药物 小肠黏膜损伤
下载PDF
药物涂层球囊与药物洗脱支架治疗冠脉小血管狭窄伴轻度钙化的疗效及安全性比较
20
作者 王月芳 《浙江实用医学》 2024年第1期6-9,45,共5页
目的比较药物涂层球囊(DCB)与药物洗脱支架(DES)治疗冠脉小血管狭窄伴轻度钙化的疗效及安全性。方法选择2020年8月~2022年10月浙江省海盐县人民医院收治的冠脉小血管狭窄伴轻度钙化患者80例,随机分为支架组(药物洗脱支架治疗)和球囊组(... 目的比较药物涂层球囊(DCB)与药物洗脱支架(DES)治疗冠脉小血管狭窄伴轻度钙化的疗效及安全性。方法选择2020年8月~2022年10月浙江省海盐县人民医院收治的冠脉小血管狭窄伴轻度钙化患者80例,随机分为支架组(药物洗脱支架治疗)和球囊组(药物涂层球囊治疗),每组40例。记录两组术前、术后和术后1年最小管腔直径、晚期管腔丢失和术后1年管腔直径净增长。统计两组术后1年内靶血管再狭窄率及心肌梗死、全因死亡、脑血管意外、靶血管重建等不良事件发生率。结果两组术前、术后以及术后1年最小管腔直径比较,差异均无统计学意义(P>0.05),但术后及术后1年与治疗前比较,最小管腔直径均有扩大(P<0.05);两组球囊组晚期管腔丢失、术后1年管腔直径净增长长度比较差异无统计学意义(P>0.05)。术后1年,两组靶血管再狭窄率(5.00%&7.50%)差异无统计学意义(χ^(2)=0.213,P=0.644)。术后6个月和1年,两组心肌梗死、全因死亡、脑血管意外、靶血管重建等不良事件发生率比较差异均无统计学意义(P>0.05)。结论药物涂层球囊用于冠脉小血管狭窄伴轻度钙化病变可达到与药物洗脱支架同样的疗效与安全性,在临床上可作为药物洗脱支架的替代治疗方案。 展开更多
关键词 冠脉小血管狭窄 轻度钙化 药物涂层球囊 药物洗脱支架 疗效 安全性
下载PDF
上一页 1 2 11 下一页 到第
使用帮助 返回顶部